What question did this study set out to answer?

To review the biological role of BAFF and its receptors in hematological malignancies and assess the current therapeutic landscape of BAFF-targeted interventions.

September 2, 2024International Journal of Clinical OncologyOpen Access

Current status of BAFF targeting immunotherapy in B-cell neoplasm

View Full Paper

Ask AI

Bookmark

Authors

NTNami TagamiSanofi (Japan)JYJunichiro YudaNational Cancer Center Hospital East YGYasuyuki GotoThe University of Tokyo

Discussion

Member takes

Implication

Review outlines therapeutic progress targeting BAFF pathways in B-cell malignancies, highlighting the potential and limitations of antibody and CAR-T approaches.

Key Points

To review the biological role of BAFF and its receptors in hematological malignancies and assess the current therapeutic landscape of BAFF-targeted interventions.
Synthesized mechanistic data from BAFF-deficient and BAFF-overexpressing murine models of lymphoproliferative disease.
Evaluated clinical trial data from investigations of anti-BAFF monoclonal antibodies (belimumab, tabalumab) and decoy receptors (atacicept).
Assessed preclinical evidence for BAFF ligand-based chimeric antigen receptor (CAR)-T cell therapies directed against BAFF receptors.
Belimumab is currently undergoing clinical investigation in combination with rituximab and venetoclax for the treatment of chronic lymphocytic leukemia.
Atacicept demonstrated clinical tolerability in a phase 1b trial for chronic lymphocytic leukemia, whereas tabalumab failed to show significant therapeutic efficacy in a phase 2 trial for relapsed/refractory multiple myeloma.
Preclinical BAFF ligand-based CAR-T cells demonstrated effective targeting of multiple BAFF receptors in models of B-cell malignancies.

Cite This Study

Tagami et al. (2024) studied this question.

synapsesocial.com/papers/6a1558bb814bf8ec9a4e719a https://doi.org/10.1007/s10147-024-02611-2

View Full Paper

Ask AI

Bookmark

Implication

Review outlines therapeutic progress targeting BAFF pathways in B-cell malignancies, highlighting the potential and limitations of antibody and CAR-T approaches.

Current status of BAFF targeting immunotherapy in B-cell neoplasm

Discussion

Member takes

Implication

Key Points

Cite This Study

Current status of BAFF targeting immunotherapy in B-cell neoplasm

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider